Revolution Medicines
Revolution Medicines is the leading RAS company, with daraxonrasib in phase 3 for pancreatic cancer.
Daraxonrasib (pan-RAS), elironrasib (G12C-selective ON), zoldonrasib (G12D); RASolute and RASolve phase 3 programmes; expanded credit facility 2025 to fund launch.
The first drug that blocks all active RAS variants, approved by the FDA in August 2026 for metastatic pancreatic cancer, where KRAS drives 90% of tumours.
A next-generation KRAS G12C drug that hits the active form of the protein, from the same company as daraxonrasib.
The first drug aimed specifically at KRAS G12D, the single most common mutation in pancreatic cancer. Early combination data in 2026 showed half of previously treated patients responding.
Pages like this
not linked directly; found by shared links- CompanyQuanta Therapeutics
Shares Covalent chemistry for the RAS mutations that still have no drug, Daraxonrasib, KRAS & RAS inhibitors, The undruggable drivers.
- IdeaRAS(ON) inhibitors to convert unresectable pancreatic cancer to resectable
Shares Zoldonrasib, Daraxonrasib, KRAS & RAS inhibitors, The undruggable drivers.
- PairingG12D-selective + pan-RAS(ON) inhibitor (zoldonrasib + daraxonrasib)
Shares Zoldonrasib, Daraxonrasib, Pancreatic ductal adenocarcinoma.
- TrialRASolute 302
Shares Daraxonrasib, KRAS & RAS inhibitors, The undruggable drivers, Pancreatic ductal adenocarcinoma.
- CompanyFrontier Medicines
Shares Covalent chemistry for the RAS mutations that still have no drug, KRAS & RAS inhibitors, The undruggable drivers, Pancreatic ductal adenocarcinoma.
- IdeaOff-the-shelf KRAS vaccines after pancreatic cancer surgery
Shares Daraxonrasib, KRAS & RAS inhibitors, The undruggable drivers, Pancreatic ductal adenocarcinoma.
- ProductMRTX1133
Shares KRAS & RAS inhibitors, The undruggable drivers, Pancreatic ductal adenocarcinoma.
- Key paperOstrem and Shokat: the hidden pocket that made KRAS G12C druggable
Shares Daraxonrasib, KRAS & RAS inhibitors, The undruggable drivers, Pancreatic ductal adenocarcinoma.